These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21612541)

  • 1. Serum APRIL, a potential tumor marker in pancreatic cancer.
    Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
    Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel serum tumor marker, RCAS1, in pancreatic diseases.
    Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
    World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer.
    Ding W; Wang J; Wang F; Wang G; Wu Q; Ju S; Cong H; Wang H
    Clin Biochem; 2013 Oct; 46(15):1590-4. PubMed ID: 23792260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
    Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
    Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
    Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
    Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
    Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
    Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.
    Reitz D; Gerger A; Seidel J; Kornprat P; Samonigg H; Stotz M; Szkandera J; Pichler M
    J Clin Pathol; 2015 Jun; 68(6):427-33. PubMed ID: 25759406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3.
    Bassi C; Salvia R; Gumbs AA; Butturini G; Falconi M; Pederzoli P
    Langenbecks Arch Surg; 2002 Nov; 387(7-8):281-5. PubMed ID: 12447553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.